| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HFABP |
| Uniprot No | P05413 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-133aa |
| 氨基酸序列 | MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDIL TLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDG QETTLVRELIDGKLILTLTHGTAVCTRTYEKEA |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HFABP(心脏型脂肪酸结合蛋白)重组蛋白的3篇示例文献，供参考：
---
1. **文献名称**：*Expression and purification of recombinant human heart-type fatty acid-binding protein in Escherichia coli*
**作者**：Glatz JFC, et al.
**摘要**：研究利用大肠杆菌表达系统高效表达重组人HFABP，通过His标签亲和层析纯化，验证其结构与天然蛋白一致，为临床检测提供原料。
2. **文献名称**：*Development of a sensitive ELISA for heart-type fatty acid-binding protein using recombinant protein*
**作者**：Wang Y, et al.
**摘要**：基于重组HFABP建立高灵敏度ELISA检测方法，验证其在心肌损伤早期诊断中的应用价值，并与商业抗体兼容性良好。
3. **文献名称**：*Recombinant HFABP as a biomarker for acute myocardial infarction: A comparative study*
**作者**：Suzuki M, et al.
**摘要**：比较重组HFABP与血清样本中天然蛋白的诊断性能，证明其作为急性心梗标志物的高特异性，支持其用于POCT设备开发。
---
**注意**：以上文献信息为示例，实际引用请通过学术数据库(如PubMed、Web of Science)核实最新研究。重组HFABP的研究多集中在诊断应用、蛋白稳定性优化及跨物种表达等领域。
Heart-type Fatty Acid-Binding Protein (HFABP) is a small cytoplasmic protein belonging to the fatty acid-binding protein (FABP) family, primarily expressed in cardiac and skeletal muscle tissues. It plays a critical role in intracellular fatty acid transport and metabolism by binding hydrophobic ligands such as long-chain fatty acids (LCFAs) and facilitating their shuttling to mitochondria or peroxisomes for β-oxidation. HFABP constitutes up to 4-8% of cytoplasmic proteins in cardiomyocytes, reflecting its importance in maintaining cardiac energy homeostasis.
Recombinant HFABP is typically produced using expression systems like *E. coli* or mammalian cells, enabling large-scale purification for research and diagnostic applications. Its low molecular weight (~15 kDa) and rapid release into circulation during myocardial injury make it a promising early biomarker for acute coronary syndromes. Studies show HFABP rises within 1-3 hours post-cardiac ischemia, preceding troponin elevations, which underscores its potential for improving early diagnosis and risk stratification in emergency settings.
Beyond diagnostics, recombinant HFABP serves as a tool to investigate lipid metabolism disorders, ischemia-reperfusion injury mechanisms, and drug development targeting fatty acid pathways. Recent research also explores its role in metabolic syndrome, diabetes, and heart failure progression. However, standardization of assays and clinical cutoff values remains a challenge, limiting widespread adoption. Ongoing efforts focus on optimizing recombinant production methods to enhance protein stability and binding affinity, while multi-marker panels integrating HFABP with other biomarkers aim to improve cardiovascular disease management.
×
